Clinical trials: Skeletal Muscle
Sarcopenia
Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly
The primary objective of this trial is to evaluate the effect of oral administration of an Astaxanthin formulation compared to placebo after one month alone and after an additional 3 months of exercise training on mitochondrial…
- Trial name
- NCT03368872
- Testing
- Astaxanthin formulation, Exercise training
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Astavita, Inc.
Fecal Incontinence
Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence
The objective of this study is the final assessment of clinical safety and efficacy of autologous autologous skeletal muscle derived cells for patients with urge fecal incontinence due to external anal sphincter dysfunction…
- Trial name
- Fidelia (NCT04976153)
- Testing
- aSMDC
- Where
- 34 sites in Austria, Bulgaria and 10 more
- Volunteers
- 290 people
- Sponsor
- Innovacell GmbH
Muscular Fatigue
Oleuropein and Muscle Energy Metabolism
Preclinical studies performed at Nestlé Research (NR) identified oleuropein as a novel activator of mitochondrial calcium import.
- Trial name
- NCT05217433
- Testing
- Olive leaf extract
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Fibrodysplasia Ossificans Progressiva
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP).
- Trial name
- ANDECAL (NCT06508021)
- Testing
- Andecaliximab
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- Ashibio Inc
Skeletal Muscle Strength & Growth
A Study to Evaluate Efficacy of EB-PA as Protein Amplifier for Skeletal Muscle Strength & Growth
The present study is a randomized, placebo-controlled, double blinded study to evaluate efficacy of EB-PA as protein amplifier for skeletal muscle strength \& growth in males with active lifestyle.
- Trial name
- NCT06127849
- Testing
- Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)
- Where
- 3 sites in India
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Skeletal Muscle Relaxation
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subjects
This is a single-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS3797 in Chinese adults.
- Trial name
- NCT05701826
- Testing
- HRS3797
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Skeletal Muscle Mitochondrial Dysfunction in the Elderly
A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly
This was a Phase 2, randomized, double-blind, placebo-controlled study, enrolling 41 elderly subjects with previous evidence of mitochondrial dysfunction to evaluate whether the administration of MTP-131 (elamipretide) will…
- Trial name
- MOTION (NCT02245620)
- Testing
- Elamipretide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stealth BioTherapeutics Inc.
Musculoskeletal Disorders, Skeletal Disorder
Observational Prospective PMCF Study to Confirm Performance and Safety of Intelect® Devices in Real World
DJO UK Ltd (ENOVIS) is conducting this study to confirm the performance and safety of the Chattanooga Intelect® devices in real world use.
- Conditions
- Musculoskeletal Disorders, Skeletal Disorder, Muscle Disorder
- Trial name
- INTELECT (NCT06809283)
- Where
- 4 sites in France, Italy and 1 more
- Volunteers
- 144 people
- Sponsor
- DJO UK Ltd
Sarcopenia
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.
- Trial name
- NCT02468674
- Testing
- bimagrumab
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Muscle Strength
Pilot Study to Evaluate Efficacy of Botanical Extracts as Protein Amplifier for Skeletal Muscle Strength & Growth.
Sponsor proposes ingredients that when added to daily whey supplementation, can lead to increased muscle strength, improves sleep quality and reduction in fatigue level.
- Trial name
- NCT04949789
- Testing
- IP I, IP II, IP III
- Where
- India
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Insulin Resistance, Obesity
Tea-beetroot-venous Occlusion Plethysmography
In the present study, muscle perfusion will be studied before and after an oral glucose challenge following a fasting period.
- Trial name
- NCT01746329
- Testing
- Tea, Beet root
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Obesity
Effects of PrimaVie and Exercise Training on Human Skeletal Muscle (PrimaVie)
PrimaVie (Natreon Inc), is a a purified and standardized shilajit extract for nutraceutical use. Research indicates that PrimaVie® has targeted action for increasing energy, revitalization and anti-aging.
- Trial name
- NCT02026414
- Testing
- PrimaVie, Exercise
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Sanni Raju
Sarcopenia, Body Composition
Validation of a Body-Composition Segmentation Software on a Diverse Public CT Scan Cohort
This study evaluates the standalone performance of Soma, a deep-learning software developed by Nucleo Research, Inc. for the automated segmentation of body-composition tissues (skeletal muscle, subcutaneous adipose tissue…
- Conditions
- Sarcopenia, Body Composition, Obesity
- Trial name
- SOMA (NCT07600866)
- Testing
- Soma Body-Composition Segmentation Software
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nucleo Research, Inc.
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving muscle function (metabolism) following moderate exercise in subjects with fatigue-Predominant Post-Acute…
- Trial name
- NCT05152849
- Testing
- AXA1125
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- Axcella Health, Inc
Age-related Muscle Decline
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
This Phase 1/2a, open-label, non-randomized study is designed to evaluate the safety and tolerability of intramuscular AAV9-Follistatin gene therapy administered either as monotherapy or in combination with a VEGF-encoding…
- Trial name
- CALM-AF-AI (NCT07443826)
- Testing
- AAV9-Follistatin gene therapy, VEGF Plasmid
- Where
- Honduras
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Unlimited Biotechnology LLC
Non-small Cell Lung Cancer (NSCLC), Cachexia
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
Study to investigate the effect of ponsegromab on skeletal muscle mass and physical function in adult participants with non-small cell lung cancer associated cachexia.
- Trial name
- NCT07663630
- Testing
- ponsegromab
- Where
- 7 sites in United States, China
- Volunteers
- 80 people
- Sponsor
- Pfizer
Fibrodysplasia Ossificans Progressiva (FOP)
A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)
Primary Objective(s): To describe the demographic characteristics of people living with FOP and a matched cohort of non-FOP people living in the United States (U.S.) To describe the prevalence of clinical characteristics of…
- Trial name
- NCT06064656
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Regeneron Pharmaceuticals
Skeletal Muscle Relaxation
A Study to Evaluate the Safety, Tolerability and Dose-Response Relationship of HRS-9190 in Healthy Subjects
This is a single-center, open-label and dose-escalation study to evaluate the safety, tolerability and dose-response relationship of HRS-9190 in healthy adults.
- Trial name
- NCT06932315
- Testing
- HRS-9190 for Injection
- Where
- China
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Sarcopenia
Dose Range Finding Study of Bimagrumab in Sarcopenia
The purpose of this study was to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia.
- Trial name
- NCT02333331
- Testing
- bimagrumab
- Where
- 58 sites in United States, Australia and 11 more
- Volunteers
- 217 people
- Sponsor
- Novartis Pharmaceuticals
Fibrodysplasia Ossificans Progressiva, FOP
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP.
- Trial name
- OPTIMA-2 (NCT07559513)
- Testing
- garetosmab
- Volunteers
- 18 people
- Sponsor
- Regeneron Pharmaceuticals